Oral News and Research

RSS

AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity

AMRI announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158(a) during the 29th Annual Scientific Meeting of the Obesity Society in Orlando, Fla.

4 Oct 2011

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Boehringer Ingelheim Canada and Eli Lilly Canada today announced that Health Canada has approved Trajenta (linagliptin), a new oral therapy to improve glycemic control in Canadian adults with type 2 diabetes.

3 Oct 2011

Combination therapy improves outcomes for liver cancer patients: Study

A combination of an oral drug, called sorafenib, and a method for injecting microbeads of chemotherapy directly into tumors has been proven safe for liver cancer patients and may improve outcomes for those who have these fast-growing, deadly tumors whose numbers are on the rise in the U.S.

1 Oct 2011

Calif. Medicaid case pits top Democrats against Obama administration

While the administration this week asked the Supreme Court to take up 26 states' challenge to the Affordable Care Act, the nation's top court on Monday will hear oral arguments on whether patients and providers can challenge states' Medicaid cuts - a case that patient advocates believe could have major implications for the implementation of health care reform.

1 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

Finally, agreement: Both sides in legal clash over health law petition high court to rule this term

News outlets examine the latest developments related to the challenges to the health law and handicap some of the possible outcomes.

1 Oct 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

UCI study shows promise of metabolic therapy for autoimmune diseases

A glucosamine-like dietary supplement suppresses the damaging autoimmune response seen in multiple sclerosis, according to a UC Irvine study.

1 Oct 2011

Patients with chronic hepatitis C less likely to take medications over time

Patients being treated for chronic hepatitis C become less likely to take their medications over time, according to a new study from the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2011

Homobrassinolide may increase appetite, muscle mass and physical performance

New research in The FASEB Journal suggests that rats fed homobrassinolide, found in the mustard plant, produced an anabolic effect, and increased appetite and muscle mass, as well as the number and size of muscle fibers.

30 Sep 2011

Oral steroid users twice as likely to have severe vitamin D deficiency

People taking oral steroids are twice as likely as the general population to have severe vitamin D deficiency, according to a study of more than 31,000 children and adults by scientists at Albert Einstein College of Medicine of Yeshiva University.

30 Sep 2011

Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated

"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.

30 Sep 2011

Oral tenofovir discontinued in HIV clinical trial

A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study cannot show that one of the study products, oral tenofovir, marketed under the trade name Viread, is effective.

29 Sep 2011

Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that researchers presented positive new data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.

29 Sep 2011

Low-tech, inexpensive interventions for bedsores could benefit long-term care residents

Researchers at the University of Toronto have found that low-tech, inexpensive interventions for bedsores could improve health for long-term care residents and reduce health-care costs for the facilities that house them.

29 Sep 2011

VOICE HIV prevention trial to discontinue use of tenofovir tablets

VOICE, an HIV prevention trial evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women - daily use of one of two different ARV tablets or of a vaginal gel - will be dropping one of the oral tablets from the study.

29 Sep 2011

Valeant's colesevelam New Drug Submission for hypercholesterolemia receives Canadian approval

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Valeant International (Barbados) SRL, has received notice that the New Drug Submission for colesevelam hydrochloride (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, has been approved by the Canadian regulatory authority Health Canada.

28 Sep 2011

Raised blood pressure may higher risk of cancer, death

Raised blood pressure is linked to a higher risk of developing cancer or dying from the disease according to the findings of the largest study to date to investigate the association between the two conditions.

27 Sep 2011

Obama administration decision could impact timing of Supreme Court ruling

The Justice Department must decide today whether to ask the full U.S. 11th Circuit Court of Appeals to reconsider a 2-1 August decision declaring unconstitutional the health law's individual mandate. If it does seek the full court's review, which could take weeks or months, it will likely push back a Supreme Court ruling until 2013.

27 Sep 2011

Oral News and Research

AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Combination therapy improves outcomes for liver cancer patients: Study

Calif. Medicaid case pits top Democrats against Obama administration

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Finally, agreement: Both sides in legal clash over health law petition high court to rule this term

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

UCI study shows promise of metabolic therapy for autoimmune diseases

Patients with chronic hepatitis C less likely to take medications over time

Homobrassinolide may increase appetite, muscle mass and physical performance

Oral steroid users twice as likely to have severe vitamin D deficiency

Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated

Oral tenofovir discontinued in HIV clinical trial

Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease

Low-tech, inexpensive interventions for bedsores could benefit long-term care residents

VOICE HIV prevention trial to discontinue use of tenofovir tablets

Valeant's colesevelam New Drug Submission for hypercholesterolemia receives Canadian approval

Raised blood pressure may higher risk of cancer, death

Obama administration decision could impact timing of Supreme Court ruling

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News